I. Focusing on Cutting-Edge Developments, Charting the Future Together

On November 30, 2025, the "Advanced Therapeutics Industry Innovation and Transformation Forum Project Roadshow Session" organized by Jiangning Pharmaceutical Valley Academy was successfully held in Nanjing Life Science and Technology Town. As an industry representative,QINGDAO AMA Co.,LTD. participated alongside the association, engaging with numerous experts, scholars, and industry peers to discuss cutting-edge trends and share innovative achievements, yielding substantial insights.

II. Gaining Insights, Grasping Industry Pulse

The forum gathered top domestic experts, scholars, and corporate representatives for in-depth discussions on cutting-edge directions such as cell and gene therapy and innovative drugs. Through multiple authoritative presentations, the company team gained a thorough understanding of the latest scientific advancements, technical pathways, and productization dynamics in China's advanced therapy sector, further clarifying industry trends and innovation directions.

At this forum, Associate Professor Xie Jinping from the Institute of Regulatory Science at China Pharmaceutical University provided an in-depth interpretation of the "Administrative Regulations on Clinical Research and Clinical Translation of New Biomedical Technologies."As a key administrative regulation in China that systematically regulates the clinical research and translation of biomedical new technologies, the "Regulations" have opened up a compliant pathway for technology translation and are of milestone significance for the development of the cell and gene therapy industry.This session provided timely and authoritative policy guidance for the company's ongoing product development, submission strategies, and clinical translation, enabling more robust and clear project planning.

III. Roadshow Presentation Showcases Innovation Capabilities

During the project roadshow segment, QINGDAO AMA Co.,LTD. delivered a thematic presentation titled "Applications of Scaffold-Free Cell Sheets: Cultivation and Utilization of Autologous Oral Mucosal Epithelial Cell Sheets and Autologous Corneal Epithelial Cell Sheets."This technology aims to replace or repair damaged corneal epithelium to improve vision. It offers significant advantages including autologous origin, absence of immune rejection, no suturing required, and acquisition of viable cell sheets with intact extracellular matrix. This drew widespread attention from attending experts, investment institutions, and industry peers.

After listening to the roadshow, experts such as Li Yuexi, Director of the East China Medical Biotechnology Research Institute, and Rui Guozhong, Secretary-General of the Biomedical Park Working Committee of the China Technology Entrepreneurship Association, gave high praise to the company's technology, expressing clear optimism about its technical prospects and clinical value. He recommended adopting a "combination of challenging and straightforward" product development strategy to optimize resource allocation and enhance overall success probability. This professional guidance holds significant practical implications for the company's subsequent R&D optimization and industrialization advancement.

IV. Outcomes and Outlook

Through this forum, QINGDAO AMA Co.,LTD. not only broadened its industry perspective and connected with cutting-edge resources but also gained multifaceted empowerment in policy understanding, technology demonstration, and expert exchanges. Moving forward, the company will continue to uphold the philosophy of "innovation-driven, transformation for the people," deepen its commitment to the cell therapy field, accelerate the clinical translation and application of its scaffold-free cell sheet technology, contribute to building an advanced therapeutic industry ecosystem, and leverage scientific and technological strength to advance human health.